Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Load children
C12N
MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
Load children
15/00
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Load children Filter patents View analytics View as hierarchy Open in page
C12N15/63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Load children Filter patents View analytics View as hierarchy Open in page
C12N15/79
Vectors or expression systems specially adapted for eukaryotic hosts
Load children Filter patents View analytics View as hierarchy Open in page
C12N15/86
Viral vectors Display name: Genetic engineering in animal cells via viral vectors
Load children Filter patents View analytics View as hierarchy Open in page
C12N15/863
Poxviral vectors,; e.g. entomopoxvirus
Load children Filter patents View analytics View as hierarchy Open in page
C12N15/8633
Avian poxviral vectors
Filter patents View analytics View as hierarchy Open in page

C12N15/8633

Avian oncolytic virus having modified sequences and uses thereof
10829786 · 2020-11-10 · ·

The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.

AVIAN ONCOLYTIC VIRUS HAVING MODIFIED SEQUENCES AND USES THEREOF
20200190538 · 2020-06-18 ·

The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.

Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom
20170137843 · 2017-05-18 · ·

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus

Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
09567606 · 2017-02-14 · ·

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.